01 June 2005 : Case report
Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancerHakan Bozcuk, Aziz Gumus, Gulay Ozbilim, Alpay Sarper, Ilknur Kucukosmanoglu, Irem H. Ozbudak, Mehmet Artac, Mustafa Ozdogan, Mustafa Samur, Abit Kaya, Burhan Savas
Med Sci Monit 2005; 11(6): HY11-20 :: ID: 16475
Background: Various biomarkers have prognostic value in non-small cell lung cancer (NSCLC). We aimed to identify the roles of P53, c-erb- B2 and p-glycoprotein (pgp) as prognostic factors, independently
or in conjunction with each other, in operable NSCLC.
Material/Methods: Seventy operable NSCLC cases were retrospectively evaluated for P53, c-erb-B2 and pgp expression patterns by immunohistochemistry. An unsupervised hierarchical cluster analysis of the 3 biomarkers was conducted. Univariate and multivariate survival analyses were made in relation to cluster affi liation.
Results: Cluster analysis yielded two distinct subgroups; group A of high biomarker expressors (n=26, 37%), and group B (n=44, 63%) of low expressors. Cluster affi liation with regard to tumor histology (interaction term) was independently associated with Recurrence- free survival (RFS) and Overall survival (OAS) with a Hazard Ratio (HR) of 5.88, P=0.003, and HR=4.68, P=0.012, respectively. The
median OAS times for cluster A and B in the squamous cell carcinoma subgroup were 328 and 596 days, whereas the corresponding fi gures in the non-squamous cell carcinoma subgroup were nonmeasurable
and 298 days.
Conclusions: In operable NSCLC there may be different relationships of P53, c-erb-B2 and pgp with patient outcome for different tumor histologies. The prognostic utility of cluster affi liation with regard to
these biomarkers, and in relation to tumor histology, deserves further testing.
Keywords: Carcinoma, Non-Small-Cell Lung - chemistry, P-Glycoprotein - analysis, Adult, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung - surgery, Cluster Analysis, Combined Modality Therapy, Lung Neoplasms - surgery, Neoplasm Staging, P-Glycoprotein - analysis, Prognosis, Receptor, erbB-2 - analysis, Risk Factors, Smoking, Survival Analysis, Tumor Markers, Biological - analysis, Tumor Suppressor Protein p53 - analysis
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic
Med Sci Monit 2021; 27:e935123
11 October 2021 : Clinical ResearchClinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...
Med Sci Monit In Press; DOI: 10.12659/MSM.933381
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-...
Med Sci Monit 2021; 27:e935123
19 Oct 2021 : Review articleRole of NLRP3 Inflammasome in Myocardial Ischemia-Reperfusion Injury and Ventricular Remodeling
Med Sci Monit In Press; DOI: 10.12659/MSM.934255
18 Oct 2021 : Clinical ResearchAdverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasth...
Med Sci Monit In Press; DOI: 10.12659/MSM.933296
13 Oct 2021 : Clinical ResearchEndovascular Repair of Thoracic Aorta Injury: 17 Years of Single-Center Experience
Med Sci Monit In Press; DOI: 10.12659/MSM.934479
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700